Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness.
Aethon Therapeutics has raised $30.0M in total funding. The most recent round was Series A. The last funding was announced in January 2023.
Aethon Therapeutics's investors include Apple Tree Partners, NYU Langone Health.
Aethon Therapeutics is headquartered in New York, United States.
Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness.
Aethon Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aethon Therapeutics — Funding & Investors." VCBacked, January 9, 2023, https://www.vcbacked.co/company/aethon-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Aethon Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/aethon-therapeutics
{{cite web |title=Aethon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aethon-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated